RxDoctor Payments Data

Craig Peters, MD

Internal Medicine · Atlanta, GANPI 1851486138

Payments from drug & device makers

$2,561in general payments, 2019–2025

Across 136 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$376
  • Lilly USA, LLC$278
  • Pfizer$259
  • Novo Nordisk$241
  • Amgen$185
  • Sanofi-aventis U.S. LLC$175
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,561 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$610,534
Medicare patients
626
Services billed
11,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate88$83,664
OzempicSemaglutide51$78,400
EliquisApixaban47$58,460
JanumetSitagliptin Phos/Metformin Hcl25$35,496
InvokanaCanagliflozin16$26,553
FarxigaDapagliflozin Propanediol11$14,930
TrulicityDulaglutide12$13,952
XareltoRivaroxaban15$13,340
LinzessLinaclotide14$10,283
DuleraMometasone/Formoterol23$9,820
MyrbetriqMirabegron11$9,693
LivaloPitavastatin Calcium18$9,472
Aimovig AutoinjectorErenumab-Aooe12$8,883
SynthroidLevothyroxine Sodium82$8,377
GlyxambiEmpagliflozin/Linagliptin12$6,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Dulera$65$128,979136 claims
Novo NordiskOzempic$241$78,40051 claims
PfizerEliquis, Premarin$259$63,99359 claims
AbbVieLinzess, Synthroid$62$18,66096 claims
AstraZenecaFarxiga$36$14,93011 claims
Lilly USA, LLCTrulicity$278$13,95212 claims
Astellas Pharma US IncMyrbetriq$125$9,69311 claims
Boehringer IngelheimGlyxambi$16$6,86612 claims
GSKAnoro Ellipta$154$6,53112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →